Investor Presentation Q1FY23

Financial Highlights: FY22 Biocon FY22 FY 21 Revenue +14% 8,397Cr *7,398Cr Core EBITDA* +18% 2,669Cr *2,270Cr % margin 32% 31% Biosimilars +24% | Research Services +19% | Generics -1% Dilution Gain in Associates of 30Cr vs 160Cr in FY21 Mark-to-market loss on investments of *28Cr; Forex Gain of *58Cr vs loss of 9Cr in FY21 EBITDA +14% 2,183Cr *1,907Cr Gross R&D spend at ₹711Cr R&D spend in P&L *595Cr % margin 26% 26% Profit Before Tax +4% 1,094Cr *1,055Cr before Exceptional Items Exceptional Loss at 111Cr % margin 13% 14% Net Profit *722Cr *744Cr Net Profit after exceptional items at *648Cr Before Exceptional Items % margin 9% 10% *Core EBITDA defined as EBITDA before forex, R&D, mark-to-market loss on investments, licensing income and gain on dilution of stake in associates. BIOCON LIMITED30

View entire presentation